(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Soleno Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast SLNO's revenue for 2025 to be $2,261,679,623, with the lowest SLNO revenue forecast at $1,189,800,711, and the highest SLNO revenue forecast at $3,467,102,453. On average, 4 Wall Street analysts forecast SLNO's revenue for 2026 to be $13,221,200,555, with the lowest SLNO revenue forecast at $11,614,289,278, and the highest SLNO revenue forecast at $16,705,588,127.
In 2027, SLNO is forecast to generate $25,643,455,729 in revenue, with the lowest revenue forecast at $25,114,823,392 and the highest revenue forecast at $26,172,088,065.